POSSIBILITIES OF USING THE QUESTIONNAIRE FOR THE EARLY DIAGNOSIS OF PRIMARY HYPERPARATHYROIDISM
DOI:
https://doi.org/10.21856/j-PEP.2023.4.11Keywords:
primary hyperparathyroidism, hypercalcemia, opportunistic screening, questionnaireAbstract
The aim of the study: to develop a questionnaire for opportunistic screening of primary hyperparathyroidism.
Materials and methods. A questionnaire for early diagnosis of the disease was developed and tested in the Department of Endocrine Surgery of the SI "V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine". The study group consisted of 50 patients who underwent surgery during 2021-2023 with a diagnosis of primary hyperparathyroidism. The control group/comparison group consisted of 138 patients without primary hyperparathyroidism who sought medical help in connection with thyroid pathology at the clinical departments of the Institute.
Results. Among the complaints, patients with primary pathology of the parathyroid glands the following prevailed: chronic pain syndrome in the upper and lower limbs, the presence of degenerative-dystrophic changes in the spine, reduced growth, cognitive impairment, the presence of arterial hypertension, shortness of breath, and urolithiasis. It is noteworthy that a certain part of the control group has each of the considered complaints, which indicates the non-specificity of such symptoms, but the frequency of the presence of some factors was probably higher against the background of primary hyperparathyroidism. Such factors include damage to the bone system: chronic pain in the limbs, a decrease in height; pathology of salt metabolism: urolithiasis and gout; vascular complications: hypertension and coronary artery disease.
Conclusions. The symptoms of primary hyperparathyroidism manifestations in general are not specific only to this pathology, but more pathognomonic are clinical manifestations from the bone system and salt metabolism. The development and implementation of an organizational algorithm for the examination of individuals with the aim of early detection of pathology looks promising.
References
Minisola S, Arnold A, Belaya Z, et al. J Bone Mineral Res 2022;37(11): 2315-2329. https://doi.org/10.1002/jbmr.4665.
Karachentsev Y, Sazonov M, Khaziev V, et al. Int J Endocrinol 2021;17(5): 377–384. https://doi.org/10.22141/2224-0721.17.5.2021.241515
Dubovyk V, Goncharova O, Dubivska S. Probl Endocrine Pathol 2021;78(4): 14-19. https://doi.org/10.21856/j-PEP.2021.4.02.
Timmons JG, Manners R, Bailey M, et al. Hormones 2021;20: 587-589. https://doi.org/10.1007/s42000-021-00292-4.
Cheren'ko SM. Pervynnyj giperparatyreoz: osnovy patogenezu, diagnostyky ta hirurgichnogo likuvannja. 2011: 148 p. http://jcees.endocenter.kiev.ua/article/view/75594/71129.
Cheren'ko SM. MJeZh. 2014;6(62): 174-181. http://nbuv.gov.ua/UJRN/Mezh_2014_6_24.
Bilezikian JP, et al. Nature Rev Dis Prim 2016;19(2): 16033. https://doi.org/10.1038/nrdp.2016.33.
Weber T, et al. Langenbecks Arch Surg 2021;406(3): 571-585. https://doi.org/10.1007/s00423-021-02173-1.
Hyperparathyroidism (primary): diagnosis, assessment and initial Management NICE guideline Published. 2019: 1-36. https:: www.nice.org. uk/guidance/ng132.
Ganesan C, Weia B, Thomas IC, et al. JAMA 2020;155(9): 861-868. https://doi.org/10.1001/jamasurg.2020.2423.
Boyd CJ, Wood KD, Singh N, et al. Int Urol Nephrol 2020;52: 1651-1655. https://doi.org/10.1007/s11255-020-02476-0.
Zhu CY, Sturgeon C, Yeh MW. JAMA. 2020;323(12): 1186-1187. https://doi.org/10.1001/jama.2020.0538.
ISSN 
ISSN 
